Q4 Earnings Estimate for BrainsWay Issued By Northland Capmk

BrainsWay Ltd. (NASDAQ:BWAY) – Research analysts at Northland Capmk boosted their Q4 2024 earnings estimates for shares of BrainsWay in a report released on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now anticipates that the company will post earnings of $0.02 per share for the quarter, up from their prior estimate of $0.01. The consensus estimate for BrainsWay’s current full-year earnings is $0.05 per share.

A number of other equities analysts also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of BrainsWay in a report on Monday, October 21st. Northland Securities increased their price target on shares of BrainsWay from $11.00 to $12.50 and gave the stock an “outperform” rating in a research note on Thursday, October 3rd.

BrainsWay Stock Performance

Shares of NASDAQ:BWAY opened at $9.12 on Friday. The firm has a market capitalization of $152.12 million, a P/E ratio of 91.21 and a beta of 1.25. The stock has a 50 day moving average price of $9.23 and a 200-day moving average price of $7.46. BrainsWay has a 52-week low of $4.30 and a 52-week high of $10.98.

BrainsWay (NASDAQ:BWAY) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. The company had revenue of $10.50 million for the quarter, compared to analysts’ expectations of $10.07 million. During the same quarter in the previous year, the company earned ($0.01) earnings per share.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its holdings in shares of BrainsWay by 10.3% during the second quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock valued at $110,000 after acquiring an additional 1,695 shares in the last quarter. Virtu Financial LLC bought a new stake in BrainsWay during the 1st quarter valued at about $60,000. Perritt Capital Management Inc purchased a new position in BrainsWay in the second quarter worth about $121,000. Good Life Advisors LLC raised its holdings in BrainsWay by 65.5% in the third quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock worth $516,000 after buying an additional 22,080 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its stake in shares of BrainsWay by 48.1% in the second quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock worth $1,567,000 after buying an additional 84,371 shares in the last quarter. Hedge funds and other institutional investors own 30.11% of the company’s stock.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.